CA2368927A1 - Quarante-cinq proteines humaines secretees - Google Patents

Quarante-cinq proteines humaines secretees Download PDF

Info

Publication number
CA2368927A1
CA2368927A1 CA002368927A CA2368927A CA2368927A1 CA 2368927 A1 CA2368927 A1 CA 2368927A1 CA 002368927 A CA002368927 A CA 002368927A CA 2368927 A CA2368927 A CA 2368927A CA 2368927 A1 CA2368927 A1 CA 2368927A1
Authority
CA
Canada
Prior art keywords
seq
sequence
polypeptide
human
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002368927A
Other languages
English (en)
Inventor
Craig A. Rosen
Steven M. Ruben
George Komatsoulis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2368927A1 publication Critical patent/CA2368927A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention a trait à de nouvelles protéines humaines sécrétées ainsi qu'à des acides nucléiques contenant les régions codantes des gènes codant ces protéines. Elle porte également sur des vecteurs, des cellules hôtes et des anticorps ainsi que sur des techniques de recombinaison permettant de mettre au point des protéines humaines sécrétées. Elle concerne, en outre, des méthodes diagnostiques et thérapeutiques, des plus utiles en matière de diagnostic et de traitement de troubles liés à ces nouvelles protéines humaines.
CA002368927A 1999-03-26 2000-03-23 Quarante-cinq proteines humaines secretees Abandoned CA2368927A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12650499P 1999-03-26 1999-03-26
US60/126,504 1999-03-26
US17484700P 2000-01-07 2000-01-07
US60/174,847 2000-01-07
PCT/US2000/007661 WO2000058495A1 (fr) 1999-03-26 2000-03-23 Quarante-cinq proteines humaines secretees

Publications (1)

Publication Number Publication Date
CA2368927A1 true CA2368927A1 (fr) 2000-10-05

Family

ID=26824732

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002368927A Abandoned CA2368927A1 (fr) 1999-03-26 2000-03-23 Quarante-cinq proteines humaines secretees

Country Status (5)

Country Link
EP (1) EP1165827A4 (fr)
JP (1) JP2002539842A (fr)
AU (1) AU3769700A (fr)
CA (1) CA2368927A1 (fr)
WO (1) WO2000058495A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259232B1 (en) * 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
US20020172995A1 (en) * 2001-05-17 2002-11-21 Wei Shao Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
DK1390403T3 (da) 2001-05-25 2007-05-14 Nymox Corp Peptider afledt af nervetrådsproteiner og medicinsk anvendelse deraf
US20030022824A1 (en) * 2001-07-10 2003-01-30 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
IL159903A0 (en) * 2001-07-19 2004-06-20 Nymox Corp Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP1847550A3 (fr) * 2001-07-19 2008-01-09 Nymox Corporation Peptides actives dans le traitement des tumeurs et autre conditions requérant la suppression ou la destruction de cellules
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU2003901511A0 (en) * 2003-03-28 2003-04-17 Bionomics Limited Nucleic acid molecules associated with angiogenesis II
US7399825B2 (en) * 2003-12-24 2008-07-15 Lipps Binie V Synthetic peptide, inhibitor to DNA viruses
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5811535A (en) * 1996-08-09 1998-09-22 Smithkline Beecham Corporation Human cartilege gp39-like gene

Also Published As

Publication number Publication date
JP2002539842A (ja) 2002-11-26
EP1165827A1 (fr) 2002-01-02
AU3769700A (en) 2000-10-16
WO2000058495A1 (fr) 2000-10-05
EP1165827A4 (fr) 2003-05-02

Similar Documents

Publication Publication Date Title
CA2368927A1 (fr) Quarante-cinq proteines humaines secretees
CA2364209A1 (fr) 49 proteines secretees humaines
CA2387696A1 (fr) 48 proteines humaines secretees
CA2364630A1 (fr) 50 proteines humaines secretees
CA2365223A1 (fr) Proteines humaines secretees (46)
CA2368281A1 (fr) 50 proteines humaines secretees
WO2000061620A1 (fr) 49 proteines humaines secretees
CA2368467A1 (fr) 50 proteines humaines secretees
CA2391364A1 (fr) 47 proteines humaines secretees
CA2368302A1 (fr) 49 proteines secretees par un etre humain
CA2365522A1 (fr) 48 proteines secretees humaines
WO2000055177A2 (fr) Proteines humaines secretees (49)
CA2391361A1 (fr) 47 proteines secretees humaines
CA2370441A1 (fr) 50 proteines humaines secretees
CA2390946A1 (fr) 49 proteines secretees humaines
CA2368442A1 (fr) 48 proteines humaines secretees
CA2368374A1 (fr) 47 proteines humaines secretees
CA2365247A1 (fr) Proteines humaines secretees (49)
CA2368719A1 (fr) Cinquante proteines humaines secretees
EP1175440A1 (fr) 48 proteines secretees humaines
CA2365238A1 (fr) 48 proteines humaines secretees
CA2368700A1 (fr) Quarante-neuf proteines humaines secretees
CA2368916A1 (fr) 49 proteines humaines secretees
CA2366691A1 (fr) 48 proteines humaines secretees
CA2368482A1 (fr) 50 proteines humaines secretees

Legal Events

Date Code Title Description
FZDE Discontinued